PO-0740: An image-guided SBRT phase II study with a dose of 42 Gy in 7 fractions for the localized prostate cancer  by Foti, C. et al.
S366                                                                                                                                         3rd ESTRO Forum 2015 
 
2Catholic University of Sacred Heart, Radiation Oncology 
Unit, Roma, Italy  
3Fondazione "Giovanni Paolo II" Catholic University of Sacred 
Heart, Radiation Oncology Unit, Campobasso, Italy  
 
Purpose/Objective: Radiation therapy (RT) after radical 
prostatectomy (RP) improves prognosis in patients with high 
risk prostate cancer. However 5-year biochemical recurrence-
free survival (bRFS) is only 75-80%. An advantage of 
hypofractionation is to reduce RT duration and to improve 
the probability of cure. However hypofractionation is 
potentially associated with an increased incidence of late 
toxicity, especially after RP. Data on efficacy and tolerability 
of hypofractionated RT in the postoperative setting are still 
lacking. Therefore, aim of this study is to compare two 
different trials using postoperative RT with conventional 
fractionation versus hypofractionation. 
Materials and Methods: In an observational study, 
postoperative RT was performed with three dimensional 
conformal radiotherapy (3DCRT) (Total dose: 70.2 Gy/1.8 Gy 
per fraction). In a fase I-II trial, postoperative RT was 
performed with intensity modulated radiotherapy (IMRT) 
using simultaneous integrated boost (SIB) technique (Total 
dose 62.5 Gy/2.5 Gy per fraction). In both trials, prophylactic 
nodal irradiation and/or adjuvant hormonotherapy were 
administered according to risk factors. bRFS (PSA < 0.2 
ng/ml), local control, disease-free-survival (DFS) and overall 
survival (OS) were analyzed using Kaplan-Meier method. A 
comparison of the survival curves was performed using long 
rank test (univariate analysis) or Cox Proportional Hazards 
Method (multivariate analysis; covariates: risk group, nodal 
irradiation and hormonotherapy duration). 
Results: Considering the two studies, 194 patients were 
enrolled. Three-year bRFS was 83.3% (pN0: 90.3% vs pN1: 
62.5%). The results are shown in Table 1. In terms of bRFS 
there was no statistical difference between the two series, 
even at multivariate analisys (p= 0.689). 
 
 
Conclusions: High dose adjuvant RT modulated based on risk 
factors (+/- prophylactic nodal irradiation, +/- adjuvant 
hormonotherapy) produced a better biochemical control 
compared to standard postoperative RT. Patients treated 
with IMRT-SIB technique showed a lower rate of acute and 
late gastrointestinal toxicity. 
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Purpose/Objective: Small bowel toxicity from external beam 
radiotherapy (EBRT) for prostate cancer is poorly predicted 
from current DVH based models. The dose absorbed by this 
mobile organ throughout a fractionated course of EBRT 
cannot easily be calculated from a single planning CT scan. 
Plasma levels of citrulline (an amino acid, secreted by the 
gut) is a putative biomarker of small bowel radiation induced 
damage and as such a decrease in levels may predict small 
bowel toxicity. In this prospective, clinical study, we 
explored the relationship between the change in plasma 
citrulline in relation to both gastrointestinal toxicity and 
small bowel dosimetry in patients receiving radical EBRT for 
prostate cancer.  
Materials and Methods: We recruited 15 patients treated 
with EBRT to either prostate only (n=6) or prostate and pelvis 
(n=9). Plasma citrulline levels were measured prior to 
radiotherapy and weekly during treatment and at 6 weeks, 3 
months and 6 months post EBRT. Bowel toxicity was assessed 
at the same time points using EPIC bowel summary scores. 
Small bowel dosimetry was calculated on a single pre-
treatment radiotherapy planning scan. 
Results: The strongest correlation between the fall in plasma 
citrulline levels from baseline and greatest bowel toxicity 
was observed after 3 weeks of radiotherapy (two tailed 
Spearman's rank test p=0.03). We further explored the ability 
of this week 3 plasma citrulline decrease to predict bowel 
toxicity up to one year post radiotherapy with two-tailed 
Spearman rank tests between radiotherapy week 3 citrulline 
change and EPIC bowel toxicity change. A strong predictive 
trend was noted with positive correlations at 6 weeks post 
radiotherapy (correlation co-efficient =0.594, p=0.025), 3 
months post radiotherapy (correlation co-efficient =0.534, 
p=0.060), 6 months post radiotherapy (correlation co-
efficient =0.606, p=0.037), 9 months post radiotherapy 
(correlation co-efficient =0.618, p=0.019) and 1 year post 
radiotherapy (correlation co-efficient =0.358, p=0.345). No 
significant correlation was found between changes in plasma 
citrulline levels or EPIC reported toxicity and the small bowel 
V15, dose to 1cm3, dose to 17cm3 or max point dose. 
Conclusions: Decreases in plasma citrulline after 3 weeks of 
pelvic EBRT may have the potential to predict small bowel 
toxicity in prostate cancer patients receiving radical external 
beam radiotherapy. Further study in a larger cohort is 
warranted. 
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Purpose/Objective: Hypofractionation for prostate cancer, 
and in particular SBRT, results in a means of radiobiological 
dose escalation and potentially represents a therapeutic gain 
and a more economical course of definitive radiation 
therapy. 
We have performed a phase II study to evaluate the 
feasibility and acute toxicity of a stereotactic body 
radiotherapy (SBRT) with a dose of 42 Gy in 7 fractions in 
patients with localized prostate cancer at low/intermediate 
risk (according to NCCN score) and risk of lymph node 
involvement <17%. 
Materials and Methods: Since 2012, 40 patients at 
low/intermediate risk for localized prostate cancer have 
been planned for SBRT [Table 1]. Fraction size is 6 Gy for 7 
fractions scheduled to be delivered twice a week for a total 
dose of 42 Gy.  
Treatment is been delivered with a VMAT technique, with 2 
arcs using 6MV photons from a Varian 2300 iX linac, planned 
with Eclipse 10.0 TPS by the AAA algorithm carried out by 3 
different planners. Dose prescription is the average dose to 
PTV with the request V95%≥ 95%.  
The DVH constraints for OAR’s have been derived from 
literature and local experience. To reduce the organ motion, 
patients has been premedicated before treatment with 
Butylscopolamine. The protocol is based on 3 IGRT 
intraprostatic fiducial markers, with daily online checks by 
CBCT. The acute and late toxicity has been recorded using 
the RTOG / EORTC scale and additional data has been 
collected by means of II-PSS (International Prostate Symptom 
Score) e IIEF-5 (International Index of Erectile Function) 
questionnaires. 
Results: Thirty-two patients have been followed for three 
months or more while thirteen patients for 12 months or 
more. At 3 month, 12% of patients reported grades 1 urinary 
toxicities . At 6 months no patients reported grade 1 urinary 
toxicities. At 18 months, one patient each reported grade 1 
proctitis and grade 1 rectal bleeding which resolved without 
intervention. 
Biochemical response was rapid the first 12 months of follow 
up: mean pre-treatment and 12-month post-treatment values 
were 3,75 ng/ml and 0.7 ng/ml respectively. 
By using pharmacological premedication of the patient we 
have a control of organ motion intrafraction (OMI) ≤ 2 mm in 
98% of treatment sessions. The results of OMI movement are 
shown in Figure 1. 
Conclusions: Intrafraction motion of the prostate is minimal 
when the patient follows the special diet and are 
premedicated before treatment with Butylscopolamine.  
The proposed scheme is estimated more effective to high-
dose conventional regimens. The absence of acute toxicity 
seems to confirm the validity of the adopted NTCP model and 
could be predictive of late toxicity. 
At this early follow up point, prostate SBRT results in 
favorable toxicity and biochemical outcomes and appears to 
support the strategy of hypofractionation in the management 
of localized prostate cancer. Further follow up is necessary 
to validate these early, promising results.  
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Purpose/Objective: Surgeons suggest an important role for 
radical prostatectomy in high risk pts. We reviewed outcomes 
and patterns of failure in high risk pts treated with conformal 
RT and androgen deprivation (ADT) to address the hypothesis 
that primary surgery offers additional benefit.  
Materials and Methods: Pt records from 11/2001- 3/2012 
were reviewed from an IRB approved database. High risk was 
defined as PSA ≥ 20 or Gleason score ≥ 8 or clinical stage ≥ 
T2c. Three treatment protocols were used: A. 2001-2009-3D 
conformal, B. 2004-2011 IMRT ± IGRT, C. 2011-2012 
VMAT+IGRT. Groups A and B were treated using standard 
2Gy/fx to 78-82 Gy. Group C was treated using hypo-
fractionation with daily IGRT to 73.6Gy/2.3Gy, (dose =82Gy 
2gy/eq., σ/β=1.5). All pts received pelvic lymph node 
radiation therapy and 2 years of ADT (except 2 patients who 
declined ADT). Side effects were recorded using CTCAE 
version 4. Treatment failure was defined using the Phoenix 
definition (PSA> absolute nadir +2ng/ml). The Kaplan Meyer 
method was used to determine probability of survival and 
toxicity. P values ≤ .05 were considered significant. 
Results: 203 patients were reviewed: Treatment group; A=30 
pts, B=71 pts, C=102 pts. Median PSA: 15.1ng/ml (range: 
1.4ng/ml – 449ng/ml). PSA< 50ng/ml=180 pts, 
PSA≥50ng/ml=23 pts. Gleason score: <7=15 pts, 7=46 pts, 
>7=142 pts. Clinical stage: <T2b=37pts, T2b=49pts, 
>T2b=117pts. Median follow up was 46 months (range: 12 -
142). Kaplan Meyer estimate of 4 year biochemical PSA free 
survival for all pts was 88%. Four year survival by subgroup 
was: treatment group: A=93%, B=90%, C=83%; PSA: PSA 
<=50ng/ml = 90%, PSA ≥ 50ng/ml = 64%; Gleason score: <7 = 
100%, 7 =87%, >7 =88%; and stage: <T2b = 97%, T2b = 89% and 
>T2b 85%. Total treatment failures: (14%, 28/203pts). 
Treatment failure by subgroup: Treatment; Group: A (17%, 
5/30 pts), B (15%, 11/71pts), C (12%, 12/102 pts) p=0.7; PSA: 
< 50 (11% , 20/180 pts), PSA ≥50 (35%, 8/23pts) p=0.03; 
Gleason score: <7 (7%, 1/15 pts), =7 (17%, 8/46pts), >7 (13%, 
19/142pts) p=0.6; and Stage: <T2b (8%, 3/37pts), T2b (13%, 
9/68pts), >T2b (16%, 16/98pts) p=0.5. Only PSA value was 
significant in uni- and multivariate analysis p=0.04. The 
median time to failure was 30m (range: 4m-76m). All failures 
were initially detected as biochemical recurrence only. Sites 
of recurrence: prostate 3pts, lymph nodes 3pts, bone 16pts, 
other 2pts, and biochemical failure 4pts. Two deaths are 
attributed to prostate cancer. Acute and late ≥grade 3 
toxicity: Genitourinary: acute 6pts (3%), late 21pts (10%); 
Gastrointestinal: acute 2pts (1%), late 7pts (3.5%). 
Conclusions: This contemporary series shows that high risk 
prostate cancer pts treated with conformal RT and ADT have 
favorable outcomes and experience low toxicity. PSA 
≥50ng/ml is associated with worse outcomes. Distant failure 
was dominant and local recurrence in the prostate was rare, 
suggesting that primary surgery is unlikely to provide 
additional benefit.   
